Incyte Corp (INCY) stock
INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/3091% above fair value
$119.09−1.18 (-0.98%)
Close on Nov 17, 2026Market cap $24.27BP/E 63.3Yield –
Incyte r&d expenses
Research and development expenses are spending on new products and technology.
Incyte's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.44B, up 80.4% year over year. For fiscal 2025 it was $2.05B, down 21.4% from the year before. Over ten years it grew 15.6% a year on average. The highest annual figure on record is $2.61B in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.05B | -21.4% |
| FY2024 | Dec 31, 2024 | $2.61B | +60.2% |
| FY2023 | Dec 31, 2023 | $1.63B | +2.6% |
| FY2022 | Dec 31, 2022 | $1.59B | +8.8% |
| FY2021 | Dec 31, 2021 | $1.46B | -34.2% |
| FY2020 | Dec 31, 2020 | $2.22B | +92.0% |
| FY2019 | Dec 31, 2019 | $1.15B | -3.7% |
| FY2018 | Dec 31, 2018 | $1.20B | -9.7% |
| FY2017 | Dec 31, 2017 | $1.33B | +127.9% |
| FY2016 | Dec 31, 2016 | $581.86M | +21.3% |
| FY2015 | Dec 31, 2015 | $479.51M | +38.0% |
| FY2014 | Dec 31, 2014 | $347.52M | +33.4% |
| FY2013 | Dec 31, 2013 | $260.44M | +23.8% |
| FY2012 | Dec 31, 2012 | $210.39M | +17.7% |
| FY2011 | Dec 31, 2011 | $178.71M | +44.3% |
| FY2010 | Dec 31, 2010 | $123.88M | +3.7% |
| FY2009 | Dec 31, 2009 | $119.44M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.79B | +253.7% |
| Q2 FY2026 | Jun 30, 2026 | $516.95M | +4.5% |
| Q1 FY2026 | Mar 31, 2026 | $515.90M | +18.0% |
| Q4 FY2025 | Dec 31, 2025 | $611.37M | +31.2% |
| Q3 FY2025 | Sep 30, 2025 | $506.58M | -11.6% |
| Q2 FY2025 | Jun 30, 2025 | $494.92M | -56.5% |
| Q1 FY2025 | Mar 31, 2025 | $437.28M | +1.9% |
| Q4 FY2024 | Dec 31, 2024 | $466.03M | +4.8% |
| Q3 FY2024 | Sep 30, 2024 | $573.17M | +52.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.14B | +184.1% |
| Q1 FY2024 | Mar 31, 2024 | $429.26M | +5.6% |
| Q4 FY2023 | Dec 31, 2023 | $444.49M | -11.3% |
| Q3 FY2023 | Sep 30, 2023 | $375.71M | -2.2% |
| Q2 FY2023 | Jun 30, 2023 | $400.75M | +15.4% |
| Q1 FY2023 | Mar 31, 2023 | $406.64M | +15.1% |
| Q4 FY2022 | Dec 31, 2022 | $501.36M | +6.0% |
| Q3 FY2022 | Sep 30, 2022 | $384.01M | +14.6% |
| Q2 FY2022 | Jun 30, 2022 | $347.20M | +1.1% |
| Q1 FY2022 | Mar 31, 2022 | $353.37M | +15.1% |
| Q4 FY2021 | Dec 31, 2021 | $472.83M | +16.5% |
| Q3 FY2021 | Sep 30, 2021 | $334.95M | -23.5% |
| Q2 FY2021 | Jun 30, 2021 | $343.51M | +19.9% |
| Q1 FY2021 | Mar 31, 2021 | $306.90M | -71.7% |
| Q4 FY2020 | Dec 31, 2020 | $405.95M | +29.8% |
| Q3 FY2020 | Sep 30, 2020 | $438.11M | +55.7% |
| Q2 FY2020 | Jun 30, 2020 | $286.60M | -1.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.09B | +301.1% |
| Q4 FY2019 | Dec 31, 2019 | $312.87M | +2.8% |
| Q3 FY2019 | Sep 30, 2019 | $281.34M | -3.8% |
| Q2 FY2019 | Jun 30, 2019 | $289.36M | -2.9% |
| Q1 FY2019 | Mar 31, 2019 | $270.55M | -10.7% |
| Q4 FY2018 | Dec 31, 2018 | $304.24M | -31.9% |
| Q3 FY2018 | Sep 30, 2018 | $292.53M | +8.5% |
| Q2 FY2018 | Jun 30, 2018 | $298.09M | +47.7% |
| Q1 FY2018 | Mar 31, 2018 | $303.10M | -25.7% |
| Q4 FY2017 | Dec 31, 2017 | $446.87M | +176.6% |
| Q3 FY2017 | Sep 30, 2017 | $269.56M | – |
| Q2 FY2017 | Jun 30, 2017 | $201.79M | – |
| Q1 FY2017 | Mar 31, 2017 | $407.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $161.59M | – |
See a number that looks wrong?